Table 1.
Study Subjects
| Non-COPD* (n=1368) |
COPD (n=1028) |
P value | |
|---|---|---|---|
| Age, yr (mean(SD)) | 63.11 (8.07) | 68.21 (8.29) | <0.01 |
| Female (%) | 712 (52.9) | 443 (43.1) | <0.01 |
| Non-Hispanic White (%) | 958 (70.0) | 832 (80.9) | <0.01 |
| FEV1% predicted (mean(SD)) | 91.68 (15.95) | 62.17 (22.45) | <0.01 |
| Bronchodilator response (%) | 129 (9.4) | 298 (29) | <0.01 |
| Inhaled corticosteroid use (%)** | 124 (9.1) | 402 (39.1) | <0.01 |
| Airway wall thickness (mean(SD)) | 0.98 (0.20) | 1.10 (0.24) | <0.01 |
| Pi10 (mean(SD)) | 2.04 (0.45) | 2.54 (0.58) | <0.01 |
| Wall area %(mean(SD)) | 47.60 (7.55) | 53.06 (8.30) | <0.01 |
| Current smokers (%) | 533 (39.0) | 331 (32.2) | <0.01 |
| Smoking history (Pack-Years, mean (SD)) | 39.10 (21.06) | 50.61 (26.05) | <0.01 |
| WBC (x103, mean(SD)) | 6.82 (1.96) | 7.37 (1.99) | <0.01 |
| Neutrophil % (mean(SD)) | 57.27 (9.80) | 61.23 (10.24) | <0.01 |
| Lymphocyte % (mean(SD)) | 31.43 (9.38) | 27.11 (9.33) | <0.01 |
| Monocyte % (mean(SD)) | 8.01 (2.36) | 8.29 (2.45) | 0.01 |
| Eosinophil % (mean(SD)) | 2.66 (1.92) | 2.75 (2.11) | 0.28 |
| Basophil % (mean(SD)) | 0.64 (0.60) | 0.61 (0.57) | 0.38 |
Abbreviations: FEV1 = forced expiratory volume in one second, NHW = non-Hispanic white, the remainder was African American. WBC = white blood cell.
including 306 subjects with preserved ratio and impaired spirometry (reduced FEV1 in the setting of a preserved FEV1/FVC[40]),
including inhaled corticosteroid and long acting beta agonist combination inhalers.
Quantitative phenotyping of segmental airways using Thirona software was performed by measuring airway dimensions in 6 bronchial paths: right upper lobe apical bronchus (RB1), right middle lobe lateral bronchus (RB4), right lower lobe posterior basal bronchus (RB10), left upper lobe apicoposterior bronchus (LB1), superior lingular bronchus (LB4) and left lower lobe posterior basal bronchus (LB10)
P values are based on t test or chi-square test for proportions